GPR7 and GPR8, structurally related orphan G-protein-coupled receptors are expressed in the central nervous system and their ligands have not been identified. Here, we report the identification of the endogenous ligand for both of these receptors. We purified the peptide ligand from porcine hypothalamus by using stable 
Introduction
Searches for ligands for orphan G-protein-coupled receptors (GPCRs) have discovered many novel peptides and have identified the receptors of bioactive substances, of which the receptors had not been known (1) (2) (3) (4) (5) (6) (7) (8) (9) .
Studies on the newly identified ligands and their receptors have given us a more precise understanding of the physiological processes involved in the endocrine, cardiovascular, reproductive, immune, inflammatory, digestive, metabolic and central nervous systems (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . In addition, these studies provide opportunities to discover innovative drugs that exert their pharmacological effects by interacting with an identified receptor as an agonist or antagonist (12) . GPR7 and GPR8, for which the ligands have not been identified, are structurally related orphan GPCRs.
Two genes of GPR7 and GPR8 were originally isolated from human genome DNA by O'Dowd et al (13) . Human GPR7 highly resembles human GPR8 with an amino acid identity of 64%. Among various families of GPCR, GPR7
and GPR8 share high similarity to the opioid and somatostatin receptor families. In mammalian brain, gene expression of GPR7 and GPR8 was detected by Northern blot and in situ hybridization analyses (13) . Especially in rat brain, GPR7 mRNA was detected in regions of the cortex, hippocampus, and hypothalamus (14) . Profiles of GPR7 and GPR8 expressed mainly in brain suggest that the endogenous ligands for the two receptors have several functions in the central nervous system.
In the present study, we report the purification, cloning, and characterization of NPW. We attempted to purify an agonist peptide for GPR8. A cDNA encoding the agonist peptide for GPR8 demonstrates the existence of NPW23 and NPW30, which exhibit no meaningful similarity to any known peptides. With the functional and binding characterization of NPW to GPR7 and GPR8, we show that NPW is the endogenous ligand for both of these receptors. In addition, we describe the in vivo effects of NPW on feeding behavior and hormone release.
Experimental Procedures
Establishment of GPR7 or GPR8-expressing Chinese hamster ovary (CHO) cell lines-The coding region of human GPR7 was cloned from human genome DNA and human brain cDNA, and that of human GPR8 was cloned from human brain cDNA by polymerase chain reaction (PCR), respectively (13) . An expression vector was constructed by ligation of the receptor gene into pAKKO-111H containing dhfr as a selection maker (15) . CHO dhfr -cells were transfected with the expression vector. The stable CHO cell lines expressing human GPR7 (CHO-GPR7) and CHO cell lines expressing human GPR8 (CHO-GPR8) were selected under conditions wherein the growth media lacked nucleotides.
Inhibition of cAMP accumulation assay-The inhibitory activity of the test samples for cAMP accumulation was measured as described (16) . CHO-GPR7 or CHO-GPR8 were plated on 24-well plates at 5 × 10 4 cells/well and cultured for two days. The cells were washed with 0.5 ml of assay buffer (Hank's buffered salt solution at pH 7.4, 0.2 mM 3-isobutyl-1-methylxantine (Wako Pure Chemical), 0.05 % bovine serum albumin, and 20 mM HEPES) for three times and cultured in the assay buffer for 30 min. After washing the cells with 0.5 ml of the assay buffer for three times repeatedly, a test sample in 0.5 ml of the assay buffer supplemented with 1 µM forskolin (Wako Pure Chemical) were added to the cells and the cells were incubated at 37°C for 30 min. cAMP synthesis in the cells was stopped by addition of 0.1 ml of 20% perchloric acid and intracellular cAMP was extracted on ice for one hour. The amount of extracted cAMP was measured using an enzyme-linked immunoassay kit (Amersham Pharmacia Biotech).
[ 35 S]-GTPγS binding assay-The [ 35 S]-GTPγS binding assay was performed essentially as described with minor modifications (12) . The human GPR8 membrane fractions suspended in 200 µl of the [ 35 S]-GTPγS assay buffer (50 mM Tris-HCl at pH 7.4, 0.1% bovine serum albumin, 5 mM MgCl 2 , 150 mM NaCl, and 1 µM GDP) was mixed with a test sample followed by addition of [ 35 S]-GTPγS (NEN Life Science Products) at a final concentration of 0.5 nM. The mixture was incubated at 25°C for 60 min and then filtered onto a GF/F glass filter.
After washing three times with 1.5 ml of the washing buffer (50 mM Tris-HCl at pH 7.4, 0.1% bovine serum albumin, 5 mM MgCl 2 , and 1mM EDTA), the glass filters were dried at 37°C for one hour. The radioactivities retained in the membranes were counted by a scintillation counter.
Purification of NPW from porcine hypothalamus-Approximately 500 g of fresh porcine hypothalamus was boiled for 10 min in water and homogenized by using a Polytron in 2 L of 1.0 M acetic acid. The homogenate was centrifuged and then the supernatant was subjected to acetone precipitation at a final acetone concentration of 66%. After removal of the precipitates, the supernatant was evaporated and extracted with diethyl ether. The resultant solution was applied to a column packed with YMCgel ODS-AM 120-S50 (YMC). The peptide fraction was eluted with 60% acetonitrile (CH 3 CN) in 0.1% trifluoroacetic acid (TFA) and the eluate was lyophilized. An agonist peptide for GPR8 was purified from the lyophilized materials by successive HPLC using a TSKgel ODS- 
Results
Purification and cDNA cloning of an agonist peptide for GPR8-We purified an agonist peptide for GPR8 from porcine hypothalamus by using stable Chinese hamster ovary cell lines expressing human GPR8 (CHO-GPR8), which is so-called '' reverse pharmacology " techniques (17) . for GPR8 with homogeneity from 500 g of porcine hypothalamus (Fig. 1, A and B) . The N-terminal amino acid sequence of the purified peptide was determined to be WYKHTASPRYHTVGRAAXLL (X, not identified), using a protein sequencer.
## Figure 1 ##
We attempted to isolate a cDNA encoding this peptide to reveal its whole amino acid sequence. We cloned a cDNA from a porcine spinal cord by the polymerase chain reaction (PCR) method using DNA sequence information obtained by both 5'-and 3'-rapid amplification of cDNA ends. Although two ATG codons present in the 5'-end region of the 565-bp cDNA precede an in-frame stop codon (DDBJ / EMBL / GenBank TM accession no. AB084277), the second ATG codon conforms more to Kozak's rules (18) . The open reading frame starting at this second ATG encodes the porcine prepro-polypeptide with 152 residues (Fig. 1C) . The PSORT II algorithm based on von Heijne's method indicates that a signal peptide cleavage site of this polypeptide resides between Ala 32
and Trp 33 (19, 20) . It is predicted that two mature peptides having 23 and 30 residues generate from the prepro- No.27 contained porcine NPW23 and NPW30, respectively (Fig. 2B ). These results demonstrate that porcine NPW23 and NPW30 existing in porcine hypothalamus activate GPR8.
## Figure 2 ##
Structure of prepro-NPW cDNA and NPW-We isolated human prepro-NPW cDNA (DDBJ / EMBL / GenBank TM accession no. AB084276) lacking an AUG starting codon from human hypothalamus and examined whether human NPW with agonist activity for GPR8 generated from this cDNA. As shown in Fig. 3 , a reading frame of the cDNA represents the amino acid sequences of 23-and 30-residue peptides, which are flanked by a signal peptide cleavage site and a pair of basic amino acid residues, and resemble porcine NPW23 and NPW30, respectively. Although an AUG starting codon is not present near the 5'-end region of the cDNA, several potential non-AUG starting codons lie within the region (22, 23) . To ensure that an agonist peptide for GPR8 is synthesized from this human cDNA, we analyzed peptides secreted from COS7 cells transfected with an expression vector containing this human cDNA. Supernatant of COS7 cells transfected with this vector showed an inhibitory effect on forskolin-induced cAMP accumulation specifically for CHO-GPR8. An agonist peptide for GPR8 was purified with homogeneity to 150 pmol from 900 ml of the supernatant (Fig. 4, A and B) . The structure of the purified peptide was determined to be WYKHVASPRYHTVGRAAGLLM (NPW21) lacking two amino acid residues at the C-terminus, compared with the predicted human NPW23 sequence. In this expression system, translation of the prepro-polypeptide and the signal peptide cleavage proceeded as expected, but the proteolytic processing at a pair of dibasic amino acid residues failed to proceed accurately. These results indicate that the agonist peptide for GPR8
generates through an intracellular processing of the prepro-polypeptide initiated from a non-AUG starting codon of the human prepro-NPW transcript.
## Figure 3 and Figure 4 ##
We compared amino acid sequences of mature NPW between species. In addition to porcine and human prepro-NPW cDNA, rat prepro-NPW cDNA (DDBJ / EMBL / GenBank TM accession no. AB084278) was cloned from rat brain. According to the prediction of the mature peptide as used for porcine prepro-NPW, we obtained mature peptide sequences having both 23 and 30 residues from porcine, rat, and human prepro-NPW ( 
## Figure 5 ##
Functional activity and binding affinity of NPW to GPR7 and GPR8-We examined the functional activity and binding affinity of synthetic NPW to human GPR7 and human GPR8, since human GPR8 shows higher similarity to human GPR7 than other numerous GPCRs. Human NPW23 dose-dependently inhibited cAMP accumulation induced by forskolin for stable CHO cell lines expressing human GPR7 (CHO-GPR7) and CHO-GPR8 with IC 50 values of 0.025 nM and 0.178 nM, respectively (Fig. 6, A and B, Table I ). Human NPW30 also showed an inhibitory effect on forskolin-induced cAMP accumulation for CHO-GPR7 and CHO-GPR8 with IC 50 values of 0.133 nM and 1.244 nM, respectively (Fig. 6, A and B, Table I ). In CHO-GPR7 and CHO-GPR8, forskolin-induced cAMP accumulation was abolished by pre-incubation with pertussis toxin (Fig. 6, C and D) , indicating that human GPR7 and human GPR8 both coupled to G protein α-subunits G i . Saturation binding analyses using [ 125 I]-labeled human NPW23 showed that CHO-GPR7 and CHO-GPR8 displayed high-affinity, saturable and specific binding (human GPR7: Kd = 31.8 ± 3.0 pM, Bmax = 2.02 ± 0.10 pmol mg -1 ; GPR8: Kd = 20.7 ± 0.6 pM, Bmax = 4.37 ± 0.04 pmol mg -1 ) (Fig. 6, E and F) . [ 125 I]-labeled human NPW23 bound both human GPR7 and human GPR8 with nearly the same affinity. Competition binding analyses demonstrated highaffinity binding of NPW23 and NPW30 to human GPR7 and human GPR8 (Table I) . NPW thus activates and binds to these receptors with high potency and affinity. These results indicate that NPW is the endogenous ligand for both GPR7 and GPR8.
## Table 1 and Figure 6 ## In vivo effects of NPW on feeding behavior and hormone release-We investigated the central effects of NPW on feeding behavior and hormone release, since rat GPR7 is expressed at relatively high levels in the brain (14) . First, human NPW23 was intracerebroventricularly administered into rats and food intake was monitored (Fig.   7A ). The injection of 10 nmol NPW23 significantly increased food intake and the magnitude of food consumption during a period of two hours was approximately 3-fold relative to vehicle controls. Second, human NPW23 was intracerebroventricularly administered into rats and the hormone concentration in the blood was measured (Fig. 7B ).
The injection of 3 nmol NPW23 significantly stimulated the release of prolactin, but not the release of other pituitary hormones such as growth hormone, adrenocorticotropic hormone, follicle-stimulating hormone, luteinizing hormone, and thyroid-stimulating hormone. Prolactin concentration increased to the maximum levels at 20 min after injection and decreased to the control levels at 60 min.
## 
Discussion
We purified NPW as an agonist peptide for GPR8 using CHO-GPR8 from porcine hypothalamus. The purified peptide is encoded in porcine prepro-NPW cDNA and the prepro-polypeptide sequence expects the existence of two mature peptides having 23 and 30 residues. We have demonstrated the existence of NPW peptides having 23 and 30 residues as mature peptides in porcine hypothalamus by the HPLC analyses combined with the [ 35 S]-GTPγS binding assay (Fig. 2, A and B) . The porcine hypothalamus contained a nearly equal amount of NPW23 and NPW30 since both fraction No. 25 and No. 27 showed nearly same agonist activity, indicating that NPW23 and NPW30 would exhibit its own biological activities in the mammalian body.
The prepro-NPW cDNA sequences suggested that the translation of human prepro-NPW, unlike that of porcine and rat, did not initiate from a typical AUG starting codon. We have demonstrated that NPW21 with an agonist activity for GPR8 is synthesized from the human NPW cDNA lacking an AUG starting codon in the transient expression system using COS7 cells. In this expression system, translation of human prepro-NPW polypeptide initiated from a non-AUG starting codon and signal peptide cleavage subsequently occurred at an expected site, but proteolytic processing of the pro-peptide failed to create an expected C terminal of mature NPW, probably due to incomplete set of processing enzymes in the COS7 cells (24) or susceptibility to the proteolysis of C terminus of mature NPW in the culture media. Natural non-AUG starting codons are very rare in eukaryotes but have been found in c-Myc, FGF-2, and VEGF (25) (26) (27) . In almost all cases, alternate initiation takes place at upstream non-AUG codons in addition to the first in-frame AUG codons. Non-AUG triplets functioning as a starting codon have been experimentally determined to be ACG, CUG, or GUG (22, 23) . If initiation of human prepro-NPW translation takes place at a position that corresponds to the AUG starting site in porcine prepro-NPW, a CUG triplet (nt 187-189) is one of the candidates for the non-AUG starting codon in human prepro-NPW (Fig.   3 ). Although further research is required to determine the translation starting site and the usage of the non-AUG starting codon in human prepro-NPW, we propose that human NPW is encoded in the cDNA of human prepro-NPW with unique translation from a non-AUG starting codon and mature forms of human NPW are NPW23
(WYKHVASPRYHTVGRAAGLLMGL) and NPW30 (WYKHVASPRYHTVGRAAGLLMGLRRSPYLW).
Human NPW23 and NPW30 showed high potency of inhibitory effects on forskolin-induced cAMP accumulation for both CHO-GPR7 and CHO-GPR8, with IC 50 values of sub-nanomolar or nanomolar levels. In the competition binding studies, human NPW23 and NPW30 showed high-affinity bindings for both GPR7 and GPR8, with IC 50 values of sub-nanomolar levels. High potency and affinity of NPW23 and NPW30 for both GPR7
and GPR8 indicate that NPW23 and NPW30 are the endogenous ligands for both GPR7 and GPR8. A slight difference between NPW23 and NPW30 was observed that NPW23 showed a tendency to activate both of GPR7
and GPR8 more efficiently than NPW30. In the inhibition of cAMP accumulation assay, IC 50 values of NPW23 for GPR7 and GPR8 were 5.3-and 7.0-fold lower than those of NPW30 for the two receptors, respectively (Table 1 ).
In contrast, NPW30 showed a tendency to bind to both of GPR7 and GPR8 with high affinity, compared with NPW23. In the competition binding assay, IC 50 values of NPW30 for GPR7 and GPR8 were 3.8-and 10.0-fold lower than those of NPW23 for the two receptors, respectively (Table 1) . C-terminal seven amino acid residues in human NPW30 should result in relatively low potency and high affinity of NPW30 for its receptors, compared with NPW23. Structure activity relationship studies of NPW are required to reveal roles of the C-terminal seven amino acid residues for activation of its receptors and binding to its receptors.
In rats, i.c.v. administration of NPW resulted in an acute increase in food intake. The orexigenic effect could be accounted for activation of GPR7-expressing neurons localized in the hypothalamic areas, which are considered to regulate feeding behavior and energy homeostasis (14, 28, 29) . Stimulation of prolactin release was observed by the i.c.v. administration of NPW. While it is known that GPR7 is expressed in pituitary gland where prolactin is secreted in response to physiological stimuli, further studies will be required to determine whether NPW activates the pituitary cells directly, or indirectly by other mechanisms (13, 30, 31) . To define the physiological importance of NPW in complex pathways of feeding and prolactin release, development of selective antagonists for the receptors of NPW and genetically engineered mice with deletion of NPW or its receptor genes will be useful. In addition to the effects of NPW on feeding and prolactin release, the broad expression patterns of GPR7 and GPR8 in mammalian brain raise the possibilities that NPW may influence many physiological processes.
Several GPCRs have more than two endogenous ligands, which activate and bind to receptors of the same family (32) . The endogenous ligands share structural similarity or common motifs among their peptide sequences and are usually encoded in different genes. GPR7 and GPR8, structurally related GPCRs are functional receptors for NPW23 and NPW30, which are encoded in a prepro-NPW gene. In our search for an endogenous ligand for GPR8,
we were unable to isolate other endogenous ligands with the structure different from NPW. However these results do not exclude the possibility that other endogenous ligands may exist for GPR7 or GPR8.
In conclusion, we have identified NPW, a novel hypothalamic peptide that is the endogenous ligand for both GPR7 and GPR8, and which affects the central control of feeding and the release of prolactin in rats. Present study will provide new insight into physiological roles of NPW and its receptors, GPR7 and GPR8. 
